Search Results - "Tato Marinho, R."

Antibiotics in acute pancreatitis in the last years – experience of a terciary referral centre by Carvalho, J., Fernandes, S., Antunes, T., Tato Marinho, R.

Get full text

Universal Access to New Generation Direct-Acting Antivirals to Reduce the Burden of Hepatitis C in Portugal by Tato-Marinho, R, Mota-Filipe, H, Martins, A.P, Martins, J, Rodrigues, J, Andreozzi, V, Vandewalle, B, Félix, J, Alves, E.C

Get full text

P653 Tight control and Treat to target increase the rates of Transmural remission and Transmural response in Crohn’s disease by Fernandes, S R, Bernardo, S, Rita Gonçalves, A, Moura dos Santos, P, Valente, A, Tato Marinho, R, Correia, L

“…Abstract Background increasing evidence support the use of Transmural remission as a treatment target in Crohn’s disease (CD) but few patients can reach it…”
Get full text

P510 Comparative effectiveness of Ustekinumab against other biologics in Inflammatory Bowel Disease: a propensity score analysis by Matos Coelho Bernardo, S, Fernandes, S, Serrazina, J, Rodrigues, I, Botto, I, Bronze, S, Gonçalves, A R, Valente, A, Santos, P M D, Tato Marinho, R, Correia, L

“…Abstract Background Background: Increasing evidence supports the use of Ustekinumab (USTK) in patients with moderate to severe Crohn’s disease (CD) and…”
Get full text

P304 Intensified versus conventional infliximab induction in acute severe steroid-refractory Ulcerative Colitis by Pedro, J, Coelho Rodrigues, I, Botto, I, Fernandes, S, Bernardo, S, Gonçalves, A R, Moura Santos, P, Valente, A, Correia, L, Tato Marinho, R

“…Abstract Background Infliximab is effective as salvage therapy in severe steroid-refractory Ulcerate Colitis. However, up to one third of patients do not…”
Get full text

P586 Surgical recurrence in Crohn’s Disease: Can we prevent it? by Botto, I, Serrazina, J, Coelho Rodrigues, I, Fernandes, S, Bernardo, S, Gonçalves, A R, Moura Santos, P, Valente, A, Correia, L, Tato Marinho, R

“…Abstract Background Crohn’s Disease (CD) is a chronic inflammatory disease primarily affecting the bowel. In the pre-biological era, approximately 40–50% of…”
Get full text

P614 Proactive infliximab is superior to either conventional infliximab and vedolizumab in Inflammatory Bowel Disease by Rodrigues, I, Serrazina, J, Botto, I, Fernandes, S, Bernardo, S, Gonçalves, A R, Moura Santos, P, Valente, A, Correia, L, Tato Marinho, R

“…Abstract Background Available evidence suggests that vedolizumab may be as effective as Infliximab (IFX) in patients with inflammatory bowel disease. However,…”
Get full text

P532 Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levels by Botto, I, Coelho Rodrigues, I, Serrazina, J, Fernandes, S, Bernardo, S, Gonçalves, A R, Moura Santos, P, Valente, A, Correia, L, Tato Marinho, R

“…Abstract Background A large body of evidence demonstrates a significant correlation between week 14 infliximab trough levels (IFXTL) and several clinical…”
Get full text

P368 Proactive Therapeutic Drug Monitoring is more effective than Conventional Management in Inducing Fecal Calprotectin remission in Inflammatory Bowel Disease by Pedro, J, Rodrigues, I, Fernandes, S, Gonçalves, A R, Bernardo, S, Baldaia, C, Valente, A, Moura Santos, P, Correia, L, Tato Marinho, R

“…Abstract Background Proactive therapeutic drug monitoring (pTDM) may potentially improve disease control and treatment outcomes in inflammatory bowel disease…”
Get full text

P428 Early and Late Fecal Calprotectin Remission - Analysis of a proactive Therapeutic Drug Monitoring Treatment Protocol by Pedro, J, Rodrigues, I, Damião, F, Fernandes, S, Gonçalves, A R, Bernardo, S, Baldaia, C, Valente, A, Moura Santos, P, Correia, L, Tato Marinho, R

“…Abstract Background Fecal calprotectin (Fc) is an adequate surrogate marker for endoscopic activity in inflammatory bowel disease. The timing of Fc remission…”
Get full text

P373 Psoriasis and psoriasiform skin lesions in patients with Inflammatory Bowel Disease treated with infliximab: a pharmacokinetic analysis by Rodrigues, I, Damião, F, Serrazina, J, Fernandes, S, Bernardo, S, Gonçalves, A R, Moura Santos, P, Baldaia, C, Valente, A, Correia, L, Tato Marinho, R

“…Abstract Background Anti-TNF agents are used to treat a variety of autoimmune conditions, including psoriasis. Paradoxically, new onset of psoriasis or…”
Get full text

SAT-256 - Universal Access to New Generation Direct-Acting Antivirals to Reduce the Burden of Hepatitis C in Portugal by Tato-Marinho, R., Mota-Filipe, H., Martins, A.P., Martins, J., Rodrigues, J., Andreozzi, V., Vandewalle, B., Félix, J., Alves, E.C.

Get full text

P645 Adalimumab drug monitoring is superior to empirical treatment adjustment in inflammatory bowel disease by CURRAIS, P, Fernandes, S, Bernardo, S, Correia, L, Gonçalves, A R, Baldaia, C, Moura Santos, P, Valente, A, Tato Marinho, R

“…Abstract Background Anti-TNF blockers are effective drugs in the treatment of inflammatory bowel disease (IBD). Therapeutic drug monitoring (TDM) of Adalimumab…”
Get full text

PIN72 - HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED TO THE MANAGEMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PORTUGAL by Placido, M., Calinas, F., Macedo, G., Maltez, F., Presa, J., Tato-Marinho, R., Valente, C., Oliveira, J., Gonçalves, M., Rabiais, S., Vandewalle, B.

Get full text

P581 Transmural remission improves clinical outcomes up to 5 years in patients with Crohn’s Disease by Pedro, J, Botto, I, Fernandes, S, Lemos, J, Neves, J, Campelo, P, Carvalho, D, Bernardo, S, Gonçalves, A R, Valente, A, Moura Santos, P, Rosa, I, Tavares de Sousa, H, Ramos, J, Venâncio, J, Leitão, J, Claro, I, Correia, L, Tato Marinho, R

“…Abstract Background Endoscopic remission (ER) is currently endorsed as one of the main treatment targets in Crohn’s Disease (CD). In a previous study, we have…”
Get full text

DOP59 Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease by Raimundo Fernandes, S, Bernardo, S, Simões, C, Correia, L, Moura Santos, P, Rita Gonçalves, A, Valente, A, Baldaia, C, Tato Marinho, R

“…Abstract Background There is increasing evidence supporting the use of therapeutic drug monitoring (TDM) of anti-TNF therapies following loss of response in…”
Get full text

P386 Association of Infliximab trough levels and perianal disease activity in Crohn’s disease by Simões, C, Fernandes, S, Bernardo, S, Gonçalves, A R, Baldaia, C, Valente, A, Moura Santos, P, Correia, L, Tato Marinho, R

“…Abstract Background Infliximab (IFX) has been proven to be efficacious in the treatment of perianal disease in patients with Crohn's disease (CD). Previous…”
Get full text

PIN87 - PHYSICIAN PREFERENCES FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION: AN ADAPTIVE CONJOINT ANALYSIS by Vandewalle, B., Calinas, F., Macedo, G., Maltez, F., Presa, J., Tato-Marinho, R., Valente, C., Oliveira, J., Placido, M., Andreozzi, V., Félix, J.

Get full text

Beyond acute abdomen by Marinho, R. Tato, Fatela, N, Baldaia, C, Ramalho, F, Velosa, J

Get full text

Intrahepatic cholestasis: Rare inaugural manifestation of AL amyloidosis by Jorge, J, Marinho, R. Tato, Fatela, N, Baldaia, C, Ramalho, F, Velosa, J

Get full text